At the 2026 American Association for Cancer Research annual meeting, researchers presented early-phase data showing that Carvykti, a BCMA-directed CAR-T cell therapy, induced deep molecular responses in 20 high-risk smoldering multiple myeloma patients, raising hopes for intercepting cancer progression in a precursor state. This approach, while promising, remains investigational and faces hurdles related to long-term safety, accessibility and the broader challenge of geographic disparities in cancer care delivery across the United States.
Intercepting Myeloma: CAR-T in Smoldering Disease
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma, characterized by clonal plasma cell proliferation without end-organ damage. In a phase 1b trial led by researchers at Dana-Farber Cancer Institute, 20 patients with high-risk SMM—defined by elevated M-protein levels and specific genetic abnormalities—received a single infusion of Carvykti (ciltacabtagene autoleucel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA). After a median follow-up of 12 months, 18 patients (90%) achieved stringent complete response, with undetectable minimal residual disease by next-generation sequencing. No patients progressed to active myeloma during the observation period. The therapy works by genetically modifying a patient’s own T cells to express a receptor that recognizes BCMA, a protein overexpressed on malignant plasma cells, leading to targeted cytotoxicity. This mechanism of action—where engineered immune cells seek and destroy specific cancer cells—represents a form of living drug with potential for durable remissions.
In Plain English: The Clinical Takeaway
For patients with high-risk smoldering myeloma—a precursor to active cancer—early use of CAR-T therapy may delay or prevent progression to symptomatic disease.
In this small study, nearly all patients achieved deep remission with no signs of residual cancer using highly sensitive tests, though long-term data are still needed.
This approach is not yet standard care and remains available only through clinical trials due to risks like cytokine release syndrome and neurotoxicity.
Geographic Disparities in Access to Advanced Therapies
Despite scientific advances, access to cutting-edge treatments like CAR-T remains unevenly distributed across the United States. A 2025 study published in JAMA Oncology found that patients living in rural counties were 40% less likely to receive CAR-T therapy compared to those in urban areas, even after adjusting for income and insurance status. This disparity stems from the concentration of certified treatment centers in academic medical hubs, requiring patients to travel hundreds of miles for apheresis, lymphodepletion chemotherapy, infusion, and post-infusion monitoring. The burden falls disproportionately on elderly patients and those without caregiver support, exacerbating existing inequities in oncology outcomes. In contrast, national healthcare systems like the UK’s NHS have begun centralizing CAR-T delivery through regional hubs with structured referral pathways, reducing geographic barriers through public funding and care coordination—models that U.S. Policymakers are beginning to study for potential adaptation.
Merck’s New Frontier in Oncology
Beyond CAR-T, Merck & Co. Presented early clinical data on a novel bispecific antibody acquired from a Chinese biotech firm, targeting both CD3 on T cells and GPRC5D on myeloma cells. In a phase 1 trial involving 45 relapsed/refractory multiple myeloma patients, the agent demonstrated an overall response rate of 60%, with 25% achieving complete response. Unlike CAR-T, which requires ex vivo cell manufacturing, bispecific antibodies are off-the-shelf therapeutics that redirect the patient’s own T cells to cancer cells upon infusion. This mechanism offers logistical advantages but carries similar risks of cytokine release and neurotoxicity. Merck plans to initiate a phase 2 trial later in 2026, with potential implications for patients who relapse after CAR-T or are ineligible due to manufacturing constraints.
Contraindications & When to Consult a Doctor
CAR-T therapy is not appropriate for all patients. Individuals with active infections, uncontrolled cardiovascular disease, or recent history of stroke should not undergo lymphodepletion chemotherapy due to increased risk of severe adverse events. Patients with prior allogeneic stem cell transplant or secondary malignancies require careful risk-benefit analysis. Symptoms warranting immediate medical attention post-infusion include fever ≥38°C, difficulty speaking, confusion, seizures, or severe hypotension—signs of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS). Anyone considering participation in a clinical trial for investigational therapies should consult a hematologist-oncologist and discuss eligibility, potential benefits, and known risks based on their disease profile and comorbidities.
Long and deep responses to CAR T-cell therapies in multiple myeloma
“The real advance here isn’t just the depth of response—it’s that we’re seeing sustained remission in a population that would otherwise progress to symptomatic myeloma within 18 to 24 months. If we can validate this in larger trials, we may shift the paradigm from treating cancer to preventing it.”
Cancer Research Carvykti
“Innovations in cancer therapy indicate little if patients can’t access them. We need to rethink how we deliver complex treatments—not just in cancer centers, but through integrated networks that bring care closer to where people live.”
Parameter
Carvykti (Ciltacabtagene autoleucel)
Bispecific Antibody (Anti-CD3xGPRC5D)
Mechanism
Autologous CAR-T targeting BCMA
Off-the-shelf bispecific T-cell engager
Administration
Single infusion post-lymphodepletion
IV infusion, typically weekly
Manufacturing
Patient-specific (~3-4 week turnaround)
Centralized manufacturing
Key Risks
CRS, ICANS, prolonged cytopenias
CRS, neurotoxicity, infections
Current Status
FDA-approved for relapsed/refractory MM
Phase 1 trial complete; Phase 2 planned
Toward Equitable Innovation in Cancer Care
The developments highlighted at AACR 2026 reflect a dual trajectory in oncology: scientific ingenuity pushing the boundaries of interception and immunotherapy, juxtaposed with persistent systemic failures in equitable delivery. While early-phase trials like the CAR-T study in smoldering myeloma offer hope for altering disease trajectories, their real-world impact will depend on addressing manufacturing bottlenecks, mitigating toxicity, and—critically—redesigning care delivery to overcome geographic and socioeconomic barriers. Regulatory bodies including the FDA and EMA continue to refine risk evaluation and mitigation strategies (REMS) for cellular therapies, but sustainable solutions require investment in community-based infusion centers, telehealth-supported monitoring, and value-based reimbursement models that incentivize access over exclusivity. Until then, breakthroughs risk benefiting only those who can reach them.
References
Ghobrial I, et al. Early use of BCMA-directed CAR-T in high-risk smoldering multiple myeloma. Presented at: American Association for Cancer Research Annual Meeting; 2026 Apr 13-16; San Diego, CA. Abstract LB-235.
Kumar S, et al. JAMA Oncol. 2025;11(4):567-574. Geographic disparities in access to chimeric antigen receptor T-cell therapy in the United States.
Raje N, et al. Lancet. 2024;403(10432):1289-1300. Bispecific antibodies targeting GPRC5D in relapsed/refractory multiple myeloma: a phase 1 study.
FDA. Risk Evaluation and Mitigation Strategies (REMS) for CAR-T Cell Therapies. Updated 2025. Https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers
WHO. Cancer prevention and control in the context of health systems strengthening. Geneva: World Health Organization; 2023.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
